Latest from Indiana University Melvin and Bren Simon Cancer Center

Olanzapine (Zyprexa) demonstrated an improvement in antinausea effects in patients receiving concurrent highly emetogenic chemotherapy and radiation therapy for advanced stage head and neck and esophageal cancer when compared to fosaprepitant.
Thousands of women have made the selfless choice to literally donate a precious piece of themselves by giving a breast tissue sample to the Susan G. Komen Tissue Bank at the Indiana University Melvin and Bren Simon Cancer Center, a unique resource for researchers worldwide.
OncLive and Indiana University Melvin and Bren Simon Cancer Center have joined forces to share news about the center's research and education programs, OncLive announced today. The collaboration is part of OncLive's Strategic Alliance Partnership initiative.
Lawrence H. Einhorn, MD, distinguished professor of medicine, division of hematology/oncology, Indiana University School of Medicine, Giant of Cancer Care: Genitourinary Cancer, discusses new methods being explored to help improve the cure rate in prostate cancer.
Einhorn, now a distinguished professor and Livestrong Foundation Professor of Oncology at the IU School of Medicine, has driven other major advances in the treatment of testicular cancer, coming up with a more effective and less toxic standard regimen and revealing important principles that are being applied to the treatment of other cancer types.
A genetic analysis resulted in the discovery of the first predictive biomarker for taxane-induced peripheral neuropathy
Publication Bottom Border
Border Publication
x